Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

nt of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... , Sept. 4, 2015  Cumberland Pharmaceuticals (CPIX), today ... present live at VirtualInvestorConferences.com on September 10, 2015. ... ET LINK: http://tinyurl.com/sep10pre ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:9/4/2015)... DUBLIN , Sept. 4, 2015  Allergan plc (NYSE: ... that Brent Saunders , CEO and President of Allergan, ... at the Morgan Stanley Global Healthcare Conference 2015 in ... http://photos.prnewswire.com/prnh/20150612/222796LOGO The presentation will take ... Time at the Grand Hyatt New York, 109 East 42nd ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3
... STXS ) today announced that executive management will ... Tuesday, September 28, 2010 at 8:30 a.m. ET in New ... of the Company,s business strategy and recent corporate developments. ... A live audio and slides webcast of Stereotaxis, presentation may ...
... Instrumentation Laboratory (IL), today announced it will host the ... 2010 at the Grand Hyatt Nusa Dua, in Bali, Indonesia. ... local time.  The forum will focus on the latest clinical ... practicing in the Asia Pacific region are welcome to attend. ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference 2Stereotaxis to Present at the JMP Securities Healthcare Conference 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 2Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 4
(Date:9/4/2015)... , ... September 04, 2015 , ... The USC Eye ... ranked number 9 nationwide by Doximity. Faculty, residents and staff are honored to ... pride in the quality of our ophthalmology residency program. Our faculty places a high ...
(Date:9/4/2015)... ... 2015 , ... Having access to a doctor can sometimes be a challenge ... unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to those ... solution to alleviate this problem has recently presented itself, the new telemedicine platform and ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in ... in the men’s 400 meters final, with an impressive 44.89 seconds at the 2015 ... Jose, Costa Rica in August 2015. The 44.64 time is a new NACAC Championship ...
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance officers deal with ... the Stark physician self-referral law. “Stark Law DOs and DON’Ts: Best Practices ... Services, Inc. (AIS), will detail which deals are attracting the most government scrutiny ...
(Date:9/4/2015)... ... September 04, 2015 , ... FiltersFast.com, the online retail ... cannot be passed up. FiltersFast.com, will ship all orders over $50.00 for ... product replacements. Take advantage of this promotion now through September 8, 2015. , ...
Breaking Medicine News(10 mins):Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2
... Vermont have uncovered the possible causes for brain disorders ... were// published November 1, 2006 in the prestigious journal ... for signaling regional blood flow changes in the brain. ... uninterrupted supply of oxygen and glucose, which is provided ...
... alcohol heavily over a short period of time or drink ... to face more depression than men, says a study.// ... Of Medicine and Health Sciences and other researchers studied the ... history of depression, according to the online edition of BBC ...
... Scientists have now uncovered graphic evidence that suggests a ... occurrence of herpes simplex infection//. The journal, Neurobiology of ... older individuals, the same gene is implicated in causing ... interest to the scientific world. It raises the possibility ...
... A compound derived from the bark of a tree could help ... new study.// ,The new molecule tazopsine was isolated ... science portal SciDev Net. ,Madagascar is an island ... It is the fourth largest island in the world and is ...
... before and for 24 hours after stent placement or ... any significant// treatment effect compared to placebo, according to ... had shown promise in preliminary studies. ,Acute ST-elevation ... following a heart attack) is a major public health ...
... issue of the Journal of the National Cancer Institute, the ... 2005 was $2.3// billion in the first year after diagnosis. ... of cancer care, but few have attempted to include a ... traveling to and from care, waiting for appointments, and receiving ...
Cached Medicine News:Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 2Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 3Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 4Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4Health News:Drug Therapy Offers Little Benefit for Some Patients Undergoing Angioplasty or Stent Procedure 2Health News:Cancer Care-Patient's Time Costs Studied 2
... the M3 and M4 monitors offer wireless ... care. M Series monitors are equipped with ... set of non-invasive parameters and input for ... extensions offer Mainstream or Microstream® CO 2 ...
Compact networked patient monitors for flexible care....
... on Philips strong heritage in patient monitoring, ... extensive clinical measurements menu; built-in clinical support ... 12-lead ECG, and arrhythmia analysis; and many ... to use and operates on a networked ...
... expands hospital-grade monitoring capabilities into the growing ... disease state management. The system is ... full range of clinical applications, from continuous ... to periodic monitoring of patients outside the ...
Medicine Products: